Shares of Surgery Partners rocketed more than 20% in pre-market trading to $19.00 after reports surfaced that Bon Secours Mercy Health, one of the largest Catholic health systems in the U.S., is in late-stage negotiations to acquire a majority stake at roughly $20 per share. The deal would mark a significant pivot for a company that has spent years building out its ambulatory surgery center portfolio — and raises an immediate question: is $20 enough? Bon Secours Nears a $6 Billion Surgery Partners Takeover — But at $20 a Share, Are Investors Getting a Fair Deal or a Fire Sale?
Shares of Surgery Partners surged more than 20% to $19.00 after the Financial Times reported that Bon Secours Mercy Health, one of America's largest Catholic hospital systems, is in late-stage talks to acquire a majority stake at roughly $20 per share. The transaction could be announced as early as Monday and would value Surgery Partners at approximately $6 billion, including about $3.5 billion in debt. The stock's leap still leaves it a dollar below the offer — a gap that prices in real uncertainty about whether the deal closes.
A 25% Premium That Still Looks Cheap Against History. The $20 offer represents a roughly 25% premium over SGRY's recent trading price near $16. But context matters: Surgery Partners' all-time high was $67.05 in June 2021 , and Bain Capital itself bid $25.75 per share in January 2025 — a proposal the board rejected. Bain then abandoned that go-private attempt at a higher valuation. Shareholders who held through the collapse are now being asked to accept 22% less than what Bain once offered.
A Debt-Heavy Company Finds a Deep-Pocketed Buyer. Surgery Partners carries net leverage of about 4.4 times its earnings before interest and other charges, and in Q2 alone, $69.8 million of its $102.1 million in operating income was consumed by interest expense. That debt burden has weighed heavily on the stock. Bon Secours, the fifth-largest Catholic health system in the U.S. with 51 hospitals and more than 1,200 care sites , brings a nonprofit balance sheet that could absorb or refinance that load — a critical lifeline Surgery Partners cannot easily create on its own.
Bain Stays In, Signaling It Sees More Upside. Bain Capital, which has held a minority investment since 2017, would retain its nearly 40% ownership stake as part of the take-private transaction. That's telling: Bain isn't cashing out, suggesting it believes the 176 surgery centers across 30 states are worth more over time. Not-for-profit hospital operators in the U.S. are pushing deeper into outpatient care through larger acquisitions , and Surgery Partners' network is exactly the kind of asset they want.
Modest Growth Makes a Buyout Easier to Justify. Surgery Partners guided for $3.35–$3.45 billion in 2026 revenue and at least $530 million in adjusted EBITDA , but it reported a $15 million net loss in Q2 and trades at just 0.6 times sales, below its historical median of 0.8 times. That discount gave Bon Secours an opening. For shareholders, the math is simple: accept $20 and a 25% windfall, or bet the board can extract more from a buyer that already knows the company is running out of negotiating leverage.